General Releases

An Update to MTX110 Study in Pediatric Patients with DIPG

An Update to MTX110 Study in Pediatric Patients with DIPG to be Presented at The International Symposium on Pediatric Neuro-Oncology, Hamburg, Germany (ISPNO 2022) Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving...

IND Application for MTX110 Study in GBM Effective

Investigational New Drug Application for Study of MTX110 in Recurrent Glioblastoma (GBM) Becomes Effective Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is...

Targeting Technology offers hope for cancer patients

This article was written by Raconteur for The Times’ Combatting Cancer publication on 30th June 2021Read the report - External link Cancer treatment has come a long way, but there are still challenges in delivering life-saving drugs to patients without compromising...

Breakthrough data using Q-Sphera technology

Breakthrough data on the successful encapsulation of a biologic using Q-Sphera technology Significant progress across multiple other R&D programmes Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the...

MTX110 Programmes to be presented at ISPNO 2020

MTX110 Programmes to be Presented at The International Symposium on Pediatric Neuro‐Oncology, Karuizawa, Japan (ISPNO 2020) Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio‐delivery and biodistribution of...

UK Parliament Highlights Need for New DIPG Treatments

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the biodelivery and biodistribution of medicines, is pleased to note that its research effort to find novel treatments for Diffuse Intrinsic Pontine Glioma ("DIPG")...

MTX110 presented at 2020 Annual SNO Conference

MTX110 Phase I Trial Results in DIPG and Preclinical Efficacy Data in Glioblastoma presented at 2020 Annual SNO Conference Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of...

UK Placing to Raise £5.0 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE...

Collaboration for the Q-Sphera platform

Midatech adds to collaborative business model for the Q-Sphera platform Midatech Pharma's next generation drug delivery technologies to be applied to new modalities in collaboration with a European pharmaceutical company. Cardiff, UK, 21 July 2020: Midatech Pharma PLC...

Research collaboration with Dr Reddy’s

Midatech enters into research collaboration with Dr Reddy's Laboratories Ltd (Dr Reddy's") Midatech Pharma's next generation drug delivery technologies for comprehensively improving bio-delivery and bio-distribution to be applied to existing medicines in collaboration...

Closing of US$3.0m Registered Direct Offering

21 May 2020Midatech Pharma PLC("Midatech" or the "Company")Midatech Pharma PLC Announces Closing of US$3.0 Million Registered Direct Offering Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and...

US$3.0 Million Registered Direct Offering

Midatech Pharma PLC("Midatech" or the "Company")Midatech Pharma PLC Announces US$3.0 Million Registered Direct Offering 18 May 2020 - Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovativeoncology and rare...

UK Placing to Raise £1.8 million

18 May 2020NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THEUNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION INWHICH OFFERS OR SALES WOULD BE PROHIBITED BY...

Midatech’s MTX110 Receives Orphan Designation for DIPG

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that the U.S. Food and Drug Administration ("FDA") has granted the Company orphan...

Headline Results of MTX110 Phase I DIPG Study

Phase II Dose Confirmed and Encouraging Survival Data Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio‐deliveryand biodistribution of medicines, is pleased to announce encouraging headline results from a...